BioAtla to Join H.C. Wainwright 26th Annual Global Investment Conference

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology firm, has announced that its management team will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The update will take the form of a pre-recorded fireside chat, which will be available on-demand starting Monday, September 9, at 7:00 a.m. ET.

BioAtla is based in San Diego, California, and operates in Beijing, China, through a partnership with BioDuro-Sundia, a preclinical development service provider. The company specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics designed to treat solid tumors. Their proprietary CAB technology enables the creation of novel, reversibly active monoclonal and bispecific antibodies, as well as other protein therapeutic candidates. These CAB product candidates are intended to offer more selective targeting, higher efficacy with reduced toxicity, and more predictable and cost-efficient manufacturing compared to traditional antibodies.

The company has secured extensive global patent coverage for its CAB technology and products, holding over 765 active patent matters, including more than 500 issued patents. This broad patent coverage spans all major markets and includes various methods of making, screening, and manufacturing CAB product candidates in diverse formats. Additionally, the patents cover the composition of matter for specific products.

BioAtla is advancing two first-in-class CAB programs currently in Phase 2 clinical trials. Mecbotamab vedotin is a conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin targets ROR2 (CAB-ROR2-ADC). Both programs aim to provide more effective treatments for solid tumors. Another promising candidate, the Phase 2 stage CAB-CTLA-4 antibody evalstotug, is designed to minimize systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors, such as anti-PD-1 antibodies.

In addition to these advanced programs, BioAtla is also developing its first dual CAB bispecific T-cell engager antibody, BA3182, which is currently in Phase 1 clinical development. BA3182 targets EpCAM, a protein highly expressed on many adenocarcinomas, while engaging human CD3-expressing T cells. Furthermore, the company has received FDA clearance for an investigational new drug (IND) application for its next-generation CAB-Nectin4-ADC, BA3361, which marks BioAtla's foray into glycoconjugates.

BioAtla's innovative approach and robust pipeline demonstrate its commitment to pioneering effective and safer treatments for cancer patients. The upcoming presentation at the H.C. Wainwright conference will provide investors and stakeholders with an in-depth look at the company’s progress and future plans.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!